Published in J Urol on January 20, 2009
EQUIL2: a BASIC computer program for the calculation of urinary saturation. J Urol (1985) 2.71
Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int (2004) 2.31
Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science (1969) 2.20
Activity products in stone-forming and non-stone-forming urine. Clin Sci (1968) 1.87
Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int (1997) 1.84
Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol (2007) 1.81
Physicochemical basis for formation of renal stones of calcium phosphate origin: calculation of the degree of saturation of urine with respect to brushite. J Clin Invest (1969) 1.54
Effect of orange juice consumption on urinary stone risk factors. J Urol (1993) 1.16
Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol (1985) 1.11
Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor. Nephrol Dial Transplant (2005) 1.11
New methods of assessing crystal growth and saturation of brushite in whole urine: effect of pH, calcium and citrate. J Urol (2008) 0.83
Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab (2004) 8.36
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem (2006) 6.50
Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol (2010) 4.59
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol (2009) 3.30
Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J (2010) 2.91
The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int (2004) 2.89
Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab (2006) 2.73
Association of urinary pH with body weight in nephrolithiasis. Kidney Int (2004) 2.67
Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int (2010) 2.50
Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int (2010) 2.35
Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A (2009) 2.23
Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension (2012) 2.23
Autophagy genes protect against Salmonella typhimurium infection and mediate insulin signaling-regulated pathogen resistance. Proc Natl Acad Sci U S A (2009) 2.21
Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol (2007) 2.02
Association of Hyperchloremia With Hospital Mortality in Critically Ill Septic Patients. Crit Care Med (2015) 1.93
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS (2012) 1.90
Echocardiographic indices do not reliably track changes in left-sided filling pressure in healthy subjects or patients with heart failure with preserved ejection fraction. Circ Cardiovasc Imaging (2011) 1.86
Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int (2012) 1.82
Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int (2002) 1.78
Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol (2013) 1.78
Effect of high protein diet on stone-forming propensity and bone loss in rats. Kidney Int (2003) 1.76
Metabolic syndrome and the risk of calcium stones. Nephrol Dial Transplant (2012) 1.71
Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin. Mol Cell Biol (2011) 1.70
Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail (2011) 1.69
Albumin regulates the Na+/H+ exchanger 3 in OKP cells. J Am Soc Nephrol (2003) 1.67
CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab (2007) 1.66
β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care (2012) 1.66
Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol (2006) 1.66
Klotho: a novel regulator of calcium and phosphorus homeostasis. Pflugers Arch (2011) 1.63
Effect of dietary modification on urinary stone risk factors. Kidney Int (2005) 1.61
Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) (2009) 1.60
Open-cell versus closed-cell stent design differences in blood flow velocities after carotid stenting. J Vasc Surg (2009) 1.58
Comparison of insulin action on glucose versus potassium uptake in humans. Clin J Am Soc Nephrol (2011) 1.57
Cloning and characterization of the human soluble adenylyl cyclase. Am J Physiol Cell Physiol (2005) 1.54
Hypercalciuria associated with high dietary protein intake is not due to acid load. J Clin Endocrinol Metab (2011) 1.54
Circadian variation in urine pH and uric acid nephrolithiasis risk. Nephrol Dial Transplant (2007) 1.51
Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort. Circ Cardiovasc Genet (2012) 1.51
Body fat content and distribution and urinary risk factors for nephrolithiasis. Clin J Am Soc Nephrol (2013) 1.51
Biochemical profile of stone-forming patients with diabetes mellitus. Urology (2003) 1.51
Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol (2009) 1.50
Effect of a culturally sensitive cholesterol lowering diet program on lipid and lipoproteins, body weight, nutrient intakes, and quality of life in patients with systemic lupus erythematosus. J Rheumatol (2002) 1.49
Etiological role of estrogen status in renal stone formation. J Urol (2002) 1.48
Recovery from skeletal fluorosis (an enigmatic, American case). J Bone Miner Res (2007) 1.48
Long-term combined treatment with thiazide and potassium citrate in nephrolithiasis does not lead to hypokalemia or hypochloremic metabolic alkalosis. Kidney Int (2003) 1.46
Defining hypercalciuria in nephrolithiasis. Kidney Int (2011) 1.44
Noninvasive quantification of pancreatic fat in humans. J Clin Endocrinol Metab (2009) 1.44
ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes. Diabetes (2005) 1.43
Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol (2010) 1.41
Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab (2012) 1.41
Renal ammonium excretion after an acute acid load: blunted response in uric acid stone formers but not in patients with type 2 diabetes. Am J Physiol Renal Physiol (2013) 1.40
Prevalence and spot urine risk factors for renal stones in children taking topiramate. J Pediatr Urol (2013) 1.39
Stimulated growth hormone concentrations in obese pediatric patients with mild and severe insulin resistance: a pilot study. J Pediatr Endocrinol Metab (2010) 1.39
Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care (2009) 1.38
Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol (2009) 1.36
Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol (2008) 1.36
Glucocorticoids acutely increase cell surface Na+/H+ exchanger-3 (NHE3) by activation of NHE3 exocytosis. Am J Physiol Renal Physiol (2005) 1.31
Vitamin D deficiency in obese children and its relationship to glucose homeostasis. J Clin Endocrinol Metab (2011) 1.27
Effect of renal lipid accumulation on proximal tubule Na+/H+ exchange and ammonium secretion. Am J Physiol Renal Physiol (2008) 1.27
The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection. Kidney Int (2013) 1.27
Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis (2012) 1.26
Functional sympatholysis is impaired in hypertensive humans. J Physiol (2011) 1.25
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology (2008) 1.24
Lipid- and mechanosensitivities of sodium/hydrogen exchangers analyzed by electrical methods. Proc Natl Acad Sci U S A (2004) 1.23
Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med (2003) 1.21
Luminal Na(+)/H (+) exchange in the proximal tubule. Pflugers Arch (2008) 1.21
Insulin activates Na(+)/H(+) exchanger 3: biphasic response and glucocorticoid dependence. Am J Physiol Renal Physiol (2002) 1.20
Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens (2004) 1.20
Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf (2007) 1.19
Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis (2006) 1.19
Monitoring protein-protein interactions between the mammalian integral membrane transporters and PDZ-interacting partners using a modified split-ubiquitin membrane yeast two-hybrid system. Mol Cell Proteomics (2008) 1.18
Rapid Communication: relative effect of urinary calcium and oxalate on saturation of calcium oxalate. Kidney Int (2004) 1.18
Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. J Urol (2003) 1.17
Ethnic differences in the frequency of ENPP1/PC1 121Q genetic variant in the Dallas Heart Study cohort. J Diabetes Complications (2007) 1.15
Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr (2007) 1.14
Secreted klotho and chronic kidney disease. Adv Exp Med Biol (2012) 1.13
Role of c-SRC and ERK in acid-induced activation of NHE3. Kidney Int (2002) 1.13
Mild hyponatremia is associated with an increased risk of death in an ambulatory setting. Kidney Int (2013) 1.12
Nephrolithiasis in children. Pediatr Nephrol (2005) 1.12